News | January 31, 2022
Pharma industry seeks fiscal support to drive innovation
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
The stability is led by healthy demand in the domestic and emerging markets
Ind-Ra expects revenue growth of over 12% in 2022.
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Subscribe To Our Newsletter & Stay Updated
